Intensity Therapeutics Set to Present Innovative Cancer Treatments at 2025 SABCS

Introduction
Intensity Therapeutics, Inc. (Nasdaq: INTS), a pioneering company in the field of cancer biotechnology, has announced that it will present two groundbreaking studies at the 2025 San Antonio Breast Cancer Symposium (SABCS) scheduled for December 9-12, 2025, in San Antonio, Texas. As a late-stage clinical biotechnology company, Intensity is focused on developing proprietary cancer therapies that leverage innovative non-covalent drug-conjugation technology to effectively target tumors and enhance the immune system's ability to recognize cancer cells.

Presentation Details

The company's presentations at the symposium will focus on two significant aspects of its research:

1. Accelerating an Anthracycline-Free Future
- Date: Thursday, December 11, 2025
- Time: 5 p.m. – 6:30 p.m. CT
- Presenter: Lewis Bender, M.S., M.A., M.B.A.
- Abstract: This presentation will discuss a new drug currently in clinical testing that offers the potential for safer and more effective combinations of breast cancer therapies without the use of anthracycline, a common chemotherapy drug.

2. Intratumoral Injections of INT230-6
- Date: Friday, December 12, 2025
- Time: 12 p.m. – 1:30 p.m. CT
- Presenter: Andreas Müller, M.D.
- Abstract: This talk will present early observations from the INVINCIBLE-4 clinical trial, which investigates the effects of INT230-6 when administered prior to neoadjuvant immuno-chemotherapy in early-stage triple-negative breast cancer patients.

About INT230-6

The lead investigational candidate, INT230-6, represents a novel approach developed through Intensity's proprietary DfuseRx℠ technology platform. This drug combines two potent anti-cancer agents—cisplatin and vinblastine sulfate—with a specially designed diffusion and cell-penetrating enhancer molecule known as “SHAO.” This formulation enables the efficient dispersion of powerful cytotoxic agents throughout tumors, enhancing drug retention within cancer cells and allowing for effective tumor reduction while minimizing exposure to the surrounding healthy tissue.

One of the significant advantages of INT230-6 is its ability to elicit strong immune responses without the immunosuppression often associated with traditional chemotherapy. This engagement helps generate a systemic anti-tumor effect, where the body's immune system is able to recognize and target cancer cells more effectively, potentially changing treatment outcomes for numerous patients diagnosed with aggressive cancer types.

Clinical Trials and Future Outlook

Intensity Therapeutics has a robust pipeline of clinical trials involving INT230-6, having previously enrolled over 200 patients across various studies, including a Phase 1/2 dose escalation trial for metastatic cancers and a Phase 2 randomized controlled trial in locally advanced breast cancer. The INVINCIBLE-3 Study is currently underway, focusing on patients suffering from soft tissue sarcoma, and reviews the effectiveness of INT230-6 as a standalone therapy compared to existing treatment standards.
Furthermore, the initiating INVINCIBLE-4 Study, in collaboration with The Swiss Group for Clinical Cancer Research, examines the usage of INT230-6 in conjunction with standard immunochemotherapy procedures pre-surgery for patients with triple-negative breast cancer.

Conclusion

The developments at Intensity Therapeutics and their upcoming presentations at the 2025 SABCS highlight the commitment to advancing breast cancer treatment through innovative methodologies. These efforts underscore the importance of tailored cancer therapies in improving patient outcomes and establishing new standards of care for various cancer types. Intensity continues to push boundaries in biotechnology, driven by its goal of transforming cancer into a manageable disease rather than a deadly diagnosis. For additional information about Intensity Therapeutics, their promising products, and intricate approaches to combating cancer, please visit their official website.